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Abstract—A medical device is designed to meet the patient
speciﬁc requirements. The required biological behaviour of the
medical device is driven by mostly the operating environment.
Most of the time, a medical device fails due to lack of under-
standing of the system requirements, including the functional
and non-functional requirements. For example, the U.S. Food
and Drug Administration (FDA) has reported a large number
of serious illnesses and deaths related to IIP. Our approach
is to trigger hidden requirements at an early stage of the
system development. In order to achieve our goal, this paper
proposes an abstract development of virtual environment model
of the glucose homeostasis for diabetes patients to analyze the
patient speciﬁc medical devices, such as an Insulin Infusion Pump
(IIP). The main objective of this environment model is to assist
in the construction, clariﬁcation, and validation of the system
requirements by developing and designing the closed-loop model
of medical devices.
Index Terms—Homeostasis, Diabetes, Formal methods, Envi-
ronment modelling.
I. INTRODUCTION
Since software plays a vital role for better controllability,
operability and safety in medical domains, the device manu-
facturers are required to validate any software used in their
devices, and test rigorously the functional behaviour of the
device for detecting critical ﬂaws and security vulnerabilities.
To address the critical ﬂaws and security vulnerabilities in-
cluding device development process, the regulators provide
guidelines to develop a safe and dependable critical medical
systems. These guidelines play a major role to comply with
certiﬁcation standards. Due to increasing system complexities,
regulatory agencies are always looking for new methods and
tools for improving the engineering-based review strategy that
could provide the system assurance.
The Insulin Infusion Pump (IIP) is a complex medical device
that is used by millions of people to regulate normal levels of
glucose for controlling diabetes. This device is used to deliver
insulin doses in a controled manner in order to maintain an
appropriate level of glucose. Over the past few years, IIPs have
been used successfully to treat diabetes. However, the failure
rate of the IIPs have increased tremendously. These failures
cause several deaths and serious illnesses. The U.S. Food
and Drug Administration (FDA) reported 17,000 adverse-
events from 2006 to 2009 including 47 deaths due to IIP’s
malfunctions [1]. The root causes of these device failures are
considered as product design and engineering ﬂaws, which
are identiﬁed by the FDA ofﬁcials during investigation of the
reported deaths and illnesses related to the IIPs.
The medical device manufacturers use an artiﬁcial environ-
ment model for simulating and testing the functionalities and
effectiveness of medical devices. Such type of environment
models are very expensive and critical to use for testing
and validating the medical devices. These models are based
on complex mathematical equations, that require high com-
putation and large memory for simulating the environment.
However, these models are not able to simulate and to check
the overall functionalities of a device. It is important to know
that, these models are also not applicable to use at the early
phases of the development life-cycle for testing or verifying
the requirements. Our experience and knowledge show that
an environment model can be used for validating the system
requirements at an early stage of the system development. This
approach has some other beneﬁts, such as ﬁnding missing
requirements, validating assumptions and strengthening the
existing requirements. To apply this approach, we need to
develop the closed-loop model by using an abstract model of
the virtual environment. The designed abstract model should
capture all the essential features. The closed-loop model is
a combined model of the medical device model and the
environment model, where both models interact to each other
using sensors and actuators. Medical device model uses ac-
tuators and sensors to respond according to the functional
activities of the virtual environment. If sensors sense abnormal
activities then the device must actuate for delivering medicine
or any other activities. If sensors sense normal behaviours then
the device should not do anything. By observing the virtual
behaviour of the environment, we can ensure that the medical
device behaves correctly under the required conditions. This
approach has potential beneﬁts of giving a conﬁdence in the
product development that the behaviour of medical device is
safe within the biological virtual environment.
As far as we know, there is no environment model for IIP,
which can be used for simulating and testing the system re-
quirements at an early stage of the system development during
design and development. This paper contributes by providing
the development of virtual environment model of the glucose
homeostasis for diabetes patients to analyze the patient speciﬁc
medical devices like Insulin Infusion Pump (IIP). The prime
use of this environment model is to assist in the construction,
clariﬁcation, and validation of the given system requirements
by designing the closed-loop model using formal methods at
an early stage of the development life-cycle. We use a simple
logic for modelling the biological environment of an IIP. The
environment model is based on continued monitoring of the
glucose-insulin regulatory system [2]. The proposed virtual
environment model describes normal and diabetic conditions,
by using α-cells and β-cells, and rising or dropping plasma
glucose level to model the pancreatic behaviour, and blood
test levels for the diagnosis of diabetes/pre-diabetes. The key
features of this model is to consider both normal and abnormal
(hyperglycemia or hypoglycemia) behaviour that can be used
to characterize a patient model. There are several beneﬁts
of our approach: 1) Development of simple and complex
environment models using simple logic in several reﬁnements;
2) Use of an environment model for identifying missing
requirements and emerging behaviour; 3) Assist in meeting
the criteria of certiﬁcation standards; and 4) Validation of the
system assumptions and behavioural requirements.
The structure of this paper is as follows. Section II presents
the related work. Section III presents basic concepts of the
virtual environment modeling. Section IV presents glucose
homeostasis (GH) system, and the formal deﬁnition of the glu-
cose homeostasis (GH) is presented in Section V. Section VI
discusses the usability of the environment model. We conclude
the paper and discuss the future work in Section VII.
II. RELATED WORK
The human biological system is one of the complex, dy-
namic and inﬁnite systems, that is not fully understood yet.
The medical practitioners and engineers use physical and
mathematical model to characterize the biological behaviour.
Over the last decade, several models exist for describing the
glucose homeostasis and diabetes. These models are either
clinical or non-clinical. The clinical models are used for
identifying and predicting the diagnostics, control, progres-
sion, complication, etc. of diabetes. The non-clinical models
are used for modelling the insulin-glucose, hepatic glucose,
glucagon, and insulin receptor dynamics, beta-cell insulin
release, and brain glucose homeostasis. The ﬁrst mathematical
model based on differential equations to model the glucose
and insulin concentration, illustrating the dynamics of insulin-
glucose for diagnostic purpose and evaluating several param-
eters of the diabetic and pre-diabetic conditions proposed
in [3]. The proposed model was very useful for describing
the dynamics of insulin and glucose and their concentra-
tion level. An integrated insulin-glucose model for analyzing
the diabetic condition using a bidirectional insulin-glucose
feedback mechanism was presented in [4]. The theoretical
treatment of the effect of external potassium on oscillations
in the pancreatic β-cells was presented in [5]. This model
was able to demonstrate that insulin infusion may be useful
for mimicking pancreatic insulin secretion. There are several
models produced by academia and industries that incorpo-
rate different physiological processes associated with insulin-
glucose dynamics and different variations [6].
The literature suggests that existing models, with their
mathematical constraints and higher order differential equa-
tions, are not easy to express in ﬁrst order logic, and thus
make it difﬁcult to express the system requirements for ver-
iﬁcation purpose. Moreover the existing models have been
developed for speciﬁc purposes that cannot support desired
global behaviours. We want to describe the complete system
by introducing the abstract notions of possible features that
can be later extended for any particular use. The concept of
environment modelling for GH system is motivated by our
previous work on heart modelling [7] and GH modelling [8].
We have adopted the same methodology to design an efﬁcient
and optimum environment model for the GH system based
on abstract notions of pancreatic behaviours. The model is
deﬁned through analyzing the glucose regulation mechanism.
The virtual environment model is described abstractly using
ﬁrst-order logic considering various safety properties at each
incremental step, and normal and abnormal behaviour (hyper-
glycemia, hypoglycemia or diabetic complications).
III. METHODOLOGY FOR ENVIRONMENT MODELLING
To use an environment model for developing the med-
ical systems, we need to focus on the expressiveness of
the selected modelling language to describe the complex
and realistic environment using various levels of abstraction.
The modelling language should have well-deﬁned syntax and
semantics for the tools to analyze desired behaviour. The
language should allow reﬁnement based modelling including
temporal, functional, reactive and non-deterministic behaviour
for specifying the required components of environment. The
Event-B modelling language fulﬁlls the basic requirements as
an environment modelling language. In fact, there is another
beneﬁt that we can also use the same modelling notations
for designing the medical systems. The reﬁnement approach
allows to model both the medical system and the environment
together to specify the required level of abstractions as well
as concrete details. Environment modelling requires higher
level of abstractions to describe non-deterministic behaviour
compared to the system behaviour. Functional behaviour of
both the environment and system models are described by
the dynamical states, which show system interactions using
sensors and actuators.
The environment model provides essential information
about environment components, basic characteristics of each
component, and structural relationship between components.
The structural relationship between two components shows
a common interface channel or medium to exchange the
information. All these components together form the overall
environment that simulates the virtual operating environment
for medical systems. Each component can have several in-
stances of the environment, which can be speciﬁed non-
deterministically for capturing the functional behaviours. The
environment model can have numerous sensors and actuators
including system components. The environment components
are described formally, and a list of properties validates the
expected functional behaviours of the components. Following,
we discuss further in detail various guidelines for modelling
the virtual environment model for medical systems [9].
A. Modelling Components
To design an environment model, we need to include all
the essential components to describe the required system
behaviour. These essential components can be expressed in
both abstract and concrete as per the granularity levels of the
system component deﬁnition. For example, few components
can be described abstractly to capture only desired behaviour
and to avoid the complex computations. Note that the complex
computation should not affect the required system behaviour.
The development of the environment model can start from a
very abstract model that can be further enriched by introducing
new components or details of the components. Each reﬁnement
level contains more components or detailed functionalities. All
the models from abstract to concrete levels can be used for
simulation purpose that can satisfy the required behaviour of
the system.
B. Components Composition
The environment components are linked to each other
through physical or logical relationships. The relationship
preserves architectural deﬁnition of the system components.
The given relationships allow all the environment components
to communicate or to exchange the information. Each com-
ponent responses according to the current actual input that
is sensed by sensors. A large system can consist of several
small components, which can be speciﬁed by functions. Each
system component uses different types of sensors that can
be described as functions with different sensors types. These
small components can be used further to design the virtual
environment model.
C. Properties of Components
To design an environment model, only components deﬁ-
nitions and relationships are not enough. These things only
provide the skeleton of an environment model, but it cannot
provide any guarantee that we have designed the correct
environment model. To design a correct environment model,
we need to provide a set of properties related to the functional
behaviours. Model properties are indispensable to charac-
terize the environment components to satisfy the required
behaviours. It is important to include those properties that are
necessary to check system requirements. These may include
behaviour constraints of a component, required input attributes
for components, and state invariants for each component
with respect to the medical systems for verifying the desired
behaviour.
D. System Modelling
To ensure the effectiveness of environment modelling, it
is important to include the system model itself for analyzing
the overall system behaviour. In fact, we need to model both
the system model and the environment model together to
understand the peculiar behaviour of the system. For instance,
to analyze an Insulin Infusion Pump (IIP), we need to model
both the IIP and GH model. However these two models
connect to each other and form a closed-loop model. These
models interface with each other as sensors and actuators. It is
important to include the details of the system and environment
model including sensors and actuators for interaction consid-
ering desired levels of detail, and required safety properties.
E. Model Simulation
The environment models developed using any methodology
require simulation and dynamic execution for understanding
the correctness of biological behaviour. The simulation allows
to check the temporal behaviour, interactions between of
system components, and new changes evolving over time.
However, it must meet all the requirements for a real biological
system. Simulation not only guarantees the correctness of sys-
tem behaviours, but also helps domain experts to understand
the designing environment.
IV. THE GLUCOSE HOMEOSTASIS SYSTEM
Glucose is the major metabolic fuel of the human body.
To maintain an appropriate level of glucose in the body and
to provide normal functionality, we need a regular supply of
glucose to the body. Failure of the glucose level causes several
diseases such as diabetes mellitus, galactosemia and glycogen
storage diseases [6].
Fig. 1 depicts the normal GH system1, which presents the
structural ﬂow of the hormones and a functional behavioural
pattern of the different organs. It is vital for the body to
maintain an appropriate glucose concentration, so both low and
high glucose levels are serious, life-threatening problems. The
body regulates its glucose concentration using the pancreas
and the liver. The pancreas produces two main hormones
insulin and glucagon to control the GH system. The body cells
use the available glucose whenever the body receives glucose
from the infusion or hepatic function. There are two different
types of cells that use the glucose. For instance, the brain
and nervous system cells use glucose without insulin, while
other types of cells like muscle and fat cells use glucose with
the help of insulin. The glucose concentration level ﬂuctuates
in the body, and is maintained in the plasma through the
pancreatic secretion of glucagon and insulin. In general, the
body attempts to maintain an appropriate level of glucose in
the body, but there are some natural stable oscillations that
occur in the glucose and insulin concentrations [2].
Low and high glucose levels are the two main biological
responses that the body uses to maintain an appropriate
plasma glucose concentration. When the glucose level drops,
then the α-cells in the pancreas produce glucagon, which
is transformed into glucose with the help of the liver. This
process helps to increase the glucose concentration in the body.
Similarly, when the plasma glucose level goes higher than
expected, then the β-cells in the pancreas are stimulated to
lower the glucose concentration [6]. This stimulation process
1The ‘normal GH system’ is when the GH system functions as it should,
i.e., there are no abnormal behaviours exhibited by the system.
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Fig. 1. The GH System (adopted from [6])
can be completed within 5 to 15 minutes, and during this
period the insulin is produced by β-cells of the pancreas. The
secreted insulin can be used by insulin dependent cells to
utilize the available glucose, and to stop the natural hepatic
glucose production for reducing the glucose concentration in
the blood. The liver is the central organ for regulation of
glucose and glycogen and behaves as a distributor of nutrients
through blood to other tissues. The presence of insulin inhibits
the transformation of glucagon to glucose.
V. FORMAL DEFINITION OF GLUCOSE HOMEOSTASIS
The GH model is mainly based on the glucose regulation
system of the body. This method uses advanced capabilities of
the combined approach of formal veriﬁcation and behaviour
simulation, in order to achieve considerable advantages for
GH system modelling. Fig. 1 shows the main components
of the GH system. The system comprises different states of
the glucose level in the blood and biological organs, in order
to control the glucose level. To formalize the GH system,
we consider eight signiﬁcant landmark nodes (Hi, No, Lo,
Ac, Bc, Li, St, Tr) in the homeostasis functional network as
shown in Fig. 2, which can control the GH system. We have
identiﬁed these landmarks through a literature survey [6], [2],
[3], [4], and use them to express an abstract functionality of
the system. We introduce the necessary elements to formally
deﬁne the GH systems as follows:
Deﬁnition 1 (The GH System). Given a set of nodes N, a
transition T, is a pair (i, j), with i, j ∈ N . A transition is
denoted by i  j. The GH system is a tuple GHS = (N, T,
N0) where:
• N = { Hi, No, Lo, Ac, Bc, Li, St, Tr } is a ﬁnite set of
landmark nodes in the GH network;
• T ⊆ N × N = {No → Hi, Hi → No, No → Lo, Lo → No,
Hi → Hi, No → No, Lo → Lo, Hi → Bc, Lo → Ac, Bc →
Li, Ac → Li, Li → St, Li → Tr, St → No, Tr → No, St →
Hi, Tr → Lo, Tr → Hi, is a set of transitions to present data
ﬂow between two landmark nodes. It should be noted that the
last three transitions are possible when we consider the case
of failure of the GH system;
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Fig. 2. The GH Automata
• N0 = No is the initial landmark node (normal glucose level);
The automata shows the ﬂow of the GH system, where by
default the GH system is considered to be in its normal state
(No). The normal state indicates that there is an appropriate
glucose level in the blood. Whenever the glucose level ﬂuc-
tuates in the blood, resulting in a high or low glucose level,
the GH system controls the ﬂuctuated glucose level with the
help of the pancreas and liver. The high and low states are
presented by Hi and Lo nodes (see Fig. 2). The pancreas has
two type of cells: α-cells and β-cells, which are indicated by
the Ac and Bc nodes, respectively. The liver is denoted by
the Li node that is used to convert the glycogen to glucose
using glucagon, and to store the glucose as glycogen in the
liver with the help of insulin. If the liver is well behaved, then
the glucose level either rises or drops according to whether
there is a low or high glucose level in the blood, respectively.
Eventually, the glucose level returns to an appropriate level.
A. Diabetes or Abnormal Homeostasis System
Fig. 3 presents abnormal behaviour of the GH system. The
liver plays a central and crucial role for regulating the glucose
level in the blood. The main task of the liver is the continual
supply of required glucose energy sources to the body. Failure
of the GH system causes several diseases, and in particular,
diabetes. There are two type of diabetes: insulin-dependent
diabetes (also know as type 1 diabetes) and non insulin-
dependent diabetes (also know as type 2 diabetes). Insulin-
dependent diabetes may be caused by insufﬁcient or no insulin
secreted due to β-cells defects. In non insulin-dependent
diabetes, insulin is produced, but the insulin receptors in the
target cells do not work due to insulin resistance in the cells, so
the insulin has no effect. In both cases there can be a very high
glucose level in the blood. Low glucose level can be caused
by α-cell defects or abnormal glucagon release, which can
be further classiﬁed as insufﬁcient or no glucagon secretion,
excess insulin, and excess glucagon secretion. Excess glucagon
secretion and defects in β-cells may also indicate a persistent
high glucose level, which can be classiﬁed as hyperglycemia-
induced diabetes complications [6].
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B. Blood Sugar Concentration
The blood sugar concentration or blood glucose level is an
amount of glucose (sugar) present in the blood of the body.
The body naturally regulates blood glucose levels as a part
of metabolic homeostasis. The glucose level ﬂuctuates many
times in a day. In general, the glucose level is always low in
the morning, and it can rise for about an hour after having
a meal. There are two types of tests used to detect abnormal
behaviours: FPG (Fasting Plasma Glucose) Test and the OGTT
(Oral Glucose Tolerance Test) [10]. The FPG test is used to
detect diabetes and pre-diabetes. The FPG test measures blood
glucose in a person who has fasted for at least 8 hours and
is most reliable when given in the morning. The OGTT can
be used to diagnose diabetes, pre-diabetes, and gestational
diabetes. This test is applied when a person has fasted for
at least 8 hours and 2 hours after the person drinks a liquid
containing 75 grams of glucose dissolved in water. The normal
glucose level should be within the range of 70 mg/dL to 99
mg/dL for a non-diabetic person using the FPG test, while the
glucose level should be within the range of 70 mg/dL to 139
mg/dL for a non-diabetic person using the OGTT [10]. In the
case of low glucose level, for both FPG and OGTT tests the
glucose level should be within the range of 0 mg/dL to 70
mg/dL. Similarly, for a high glucose level, readings should be
greater than 126 mg/dL in the FPG test, and greater than 140
mg/dL using the OGTT. A blood sugar level outside of the
normal range indicates an abnormal glucose concentration. A
high level of glucose is referred to as hyperglycemia and a
low level of glucose is referred to as hypoglycemia.
Property 1 (Glucose level in blood). The blood glucose level
deﬁnes different stages, such as hyperglycemia, hypoglycemia
and normal. We say that the glucose level is low (hypo-
glycemia) if FPG ∈ 0..69 or OGTT ∈ 0..69, and the glucose
level is high (hyperglycemia) if FPG ≥ 126 or OGTT ≥ 200,
and the glucose level is normal if FPG ∈ 70 .. 99 or
OGTT ∈ 70 .. 139. We classify pre-diabetes to be the range
where FPG ∈ 100 .. 125 or OGTT ∈ 140 .. 199.
C. Formalization of the GH System
To develop a virtual biological environment of GH based
on formal techniques, we use the Event-B modelling lan-
guage [11] that supports an incremental reﬁnement to design
a complete system in several layers, from an abstract to a con-
crete speciﬁcation. Initial model captures the basic behaviour
and biological requirements of the GH system in an abstract
way. The subsequent reﬁnements are used to introduce α-
cells and β-cells of the pancreas, functional behaviour of liver
to convert and to store the glucose, abnormal conditions of
the pancreas, diabetic conditions, and diabetes complications,
and blood sugar concentration for assessing diabetes. The
developed system results the dynamic behaviours of virtual
GH biological environment that covers the both normal and
abnormal behaviours (hyperglycemia, hypoglycemia or dia-
betic complications). A list of safety properties are deﬁned at
each incremental level to guarantee the correctness of designed
virtual biological environment model for GH. A detail formal-
ization process of the virtual biological environment model is
available in [8].
VI. USABILITY OF ENVIRONMENT MODEL
This section presents usability of environment modelling for
developing an IIP as follows:
A. Verifying patient safety in closed-loop
The closed-loop system allows to monitor according to
the system requirements as per the physiological needs. Each
patient has speciﬁc needs according to the diabetic symptoms,
which can be diagnosed by using an IIP. In fact, an IIP has
conﬁguration parameters that allow to conﬁgure the device for
each patient by doctors by analyzing the chronicle conditions.
To verify at an early stage of the system development, the
environment model can be used by developing a close-loop
system. Environment models describe normal and abnormal
conditions of patients that can be helpful to analyze the IIP
requirements and to check consistencies for ﬁnding missing
requirements. The integration of the environment modelling
and IIP allows to evaluate whether the IIP provides an appro-
priate therapy for diabetes as per the patient needs without
delivering excessive insulin.
B. Checking functional requirements
The closed-loop system exposes several conditions for nor-
mal and abnormal diabetic conditions, which are represented
in (Fig. 3) using a range of situations that occur due to several
types of malfunctions. The state of glucose homeostasis is
presented as a boolean state to show normal and abnormal
states. The insulin delivery mechanism is speciﬁed under
various conditions. Some behaviour requirements are given
as follows: 1) β-cells and α-cells defects cause high plasma
glucose level. It is important that insulin must be released in
an appropriate amount to stabilize the glucose level. 2) Insulin
resistance in cells does not allow to reduce the high plasma
glucose level, where an IIP requires to delivery insulin to
control the glucose level. 3) Abnormal glucagon release also
causes excessive glucagon secretion that maintains the high
plasma glucose level. However, the IIP must deliver insulin
as per the body requirements. We have discussed various
abnormal behaviours of patients. These scenarios must be
covered in the environment model and the closed-loop model
should provide evidence that the IIP delivers insulin doses
whenever they are required by the patient. The insulin delivery
process must be coordinated with GH model to ensure required
amount of insulin for maintaining the normal glucose level.
C. Analyzing clinical requirements
Clinical requirements depend on the patient needs such as
insulin resistance in cell, β-cells defect, α-cells defect, insufﬁ-
cient insulin secretion, insufﬁcient glucagon secretion, excess
insulin and excess glucagon secretion. These requirements are
common critical conditions, which can vary for each patient
because of different physiological needs.
The GH model is presented as abstract as possible to capture
all possible scenarios of the natural glucose homeostasis sys-
tem. Whenever, the functional behaviour of α-cells and β-cells
change; or insulin and glucagon releasing behaviour change;
or the functional behaviour of natural glucose homeostasis
change, the glucose levels, which represents high plasma
glucose level or low plasma glucose level will be affected.
Moreover, we introduce other abnormal condition details, and
blood sugar concentration using stepwise reﬁnement. The
present model is still abstract to cop with several major normal
and abnormal conditions. For instance, we have not done any
special treatment in our model to capture the required time
duration to stabilise the normal glucose level after releasing
insulin. The timing requirements can vary for each patients and
it results in many symptoms, primarily those symptoms result
from the delayed, non-physiologic timing of insulin release in
relation to high glucose level. The normal and abnormal states
of GH model are represented through the abstract behaviour,
and α-cells and β-cells release functions requirements. In case
of abnormal state of the glucose homeostasis, the IIP delivers
the required amount of insulin to maintain the glucose level.
D. Finding essential safety properties
The closed-loop model provides higher assurance for safety
and security. The environment based closed-loop modelling
approach offers to ﬁnd ambiguities and inconsistencies in the
IIP speciﬁcation. The abstract representation and set theory
allow to software engineers to specify system requirements and
desired safety properties. The generated proof obligations and
discharging them show the correctness of system requirements
according to the deﬁned properties. Any inconsistencies be-
tween requirements are identiﬁed and fed back to main system
requirements. This iterative process allow to ﬁnd the correct
requirements as per deﬁned notions of the environment.
Another beneﬁt of this approach is that the environment
model can be reused with other systems, wherever a system
requires environment modelling for veriﬁcation and validation.
This environment is always considered as a separate system,
which can be further changed as per stakeholder demands
for multiple purposes, such as simulation and testing. Each
time this environment model can produce a different set of
safety properties according to the integration of a new device
speciﬁcation.
VII. CONCLUSION AND FUTURE CHALLENGES
There are several existing clinical models based differential
equations and higher order polynomial equations that require
signiﬁcant computation and a large memory for implementa-
tion, which cannot be used at the early stage of the system
development for developing the closed-loop model for verify-
ing a IIP. In this paper, we have presented a methodology
for modelling a biological environment of the GH using
simple logical mathematics in an abstract way to simulate the
desired behaviour to avoid the mathematical complexity. This
is the ﬁrst computational model based on logical concepts to
simulate the GH behaviour in order to analyze the normal
and diabetic conditions. The developed model highlights a
different aspect of the problem, making different assumptions
and establishing different properties concerning the variation
in glucose levels, normal and diabetic conditions, and mal-
function of biological organs like the liver and pancreas. This
is a promising simulated biological environment model that
can be used to develop a closed-loop model of the biological
environment and IIP. As we know that the FDA has already
reported several recalls related to IIP, so our approach may
help to identify the possible bugs in early phase of the
development life-cycle of IIP. Our most important contribution
is that this formal model helps to obtain certiﬁcation for the
medical devices related to the homeostasis system, such as IIP.
This environment model can also be used as a diagnostic tool
to diagnose or understand patient requirements.
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